Physician

Daniel B Salvas, M.D.

According to 2025 Medicare claims, Daniel Salvas, M.D. (NPI: 1811912140) practices urology in the Indianapolis-Carmel-Greenwood, IN market, with the plurality of this provider's patient population coming from Marion, IN. This provider's primary affiliated billing organization is UROLOGY OF INDIANA L.L.C. (NPI: 1487680518; TIN: 35-1998209) and primary practice location at 46143-1049. Salvas is affiliated with the Central Florida ACO (ACO ID: A2801), participating under the MSSP model.

Salvas' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 2,972 traditional Medicare patients, billed 40,912 HCPCS/CPT codes, and received $1,587,316 in Medicare payments. The top billing code was 84153 (Psa (prostate specific antigen) measurement, total). Part D data shows 3,891 prescription claims across 842 beneficiaries totaling $290,933 in drug costs, led by Gemtesa (Vibegron). DME data shows 57 claims. Open Payments data shows 30 records totaling $15,931. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $293,676 to $1,587,316. Concurrently, Part D prescription costs have changed little. In contrast, DME billing represents a smaller volume and did not follow a clear longitudinal pattern.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,026	10,626	$293,676
2016	2,771	16,568	$352,021
2017	1,910	11,789	$324,530
2018	2,700	14,844	$321,894
2019	3,476	54,630	$450,553
2020	2,884	47,907	$406,230
2021	2,687	30,595	$364,281
2022	2,781	10,043	$324,664
2023	2,515	39,941	$317,904
2024	2,972	40,912	$1,587,316

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	625	3,306	$183,479
2016	778	3,712	$212,512
2017	768	4,139	$272,480
2018	751	3,797	$283,647
2019	749	3,421	$247,370
2020	743	3,431	$229,431
2021	745	3,311	$234,033
2022	724	3,246	$269,103
2023	746	3,385	$250,133
2024	842	3,891	$290,933

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	119	$19,297
2016	N/R	98	$26,843
2017	22	130	$43,393
2018	13	146	$47,145
2019	12	134	$51,583
2020	11	97	$42,726
2021	N/R	87	$51,197
2022	N/R	58	$26,988
2023	N/R	45	$26,971
2024	N/R	57	$32,610

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
84153	Psa (prostate specific antigen) measurement, total	757	853	$18
74018	X-ray of abdomen, 1 view	561	673	$14
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	357	505	$12
87086	Bacterial colony count, urine	460	507	$8
81001	Manual urinalysis test with examination using microscope, automated	426	634	$3

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Gemtesa	Vibegron	109	5,747	$90,548
Myrbetriq	Mirabegron	82	5,560	$84,537
Elmiron	Pentosan Polysulfate Sodium	16	660	$22,519
Trospium Chloride	Trospium Chloride	206	11,073	$13,921
Testosterone	Testosterone	21	1,182	$10,531

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4352	Intermittent urinary catheter; coude (curved) tip, with or without coating (teflon, silicone, silicone elastomeric, or hydrophilic, etc.), each	N	N/R	22	$22,954
A4351	Intermittent urinary catheter; straight tip, with or without coating (teflon, silicone, silicone elastomer, or hydrophilic, etc.), each	N	N/R	20	$9,268
A4332	Lubricant, individual sterile packet, each	N	N/R	15	$388

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	29	$15,931	Central Indiana URS Consumables, LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	1	$10,480	Central Indiana URS Consumables, LLC

Explore More Providers

FAQ

What Medicare data is available for Daniel B. Salvas, M.D.?

Tedicare shows public-source Medicare data for Daniel B. Salvas, M.D. (NPI 1811912140), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Daniel B. Salvas, M.D. have ACO affiliation data?

Daniel B. Salvas, M.D. is shown with ACO affiliation data for Central Florida ACO (MSSP, ACO ID A2801).

What billing organization is linked to Daniel B. Salvas, M.D.?

Daniel B. Salvas, M.D. is linked to UROLOGY OF INDIANA L.L.C. (billing NPI 1487680518) in the available physician profile data.

Does Daniel B. Salvas, M.D. have Open Payments data?

Daniel B. Salvas, M.D. has 30 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.